JP5189067B2 - 血清および血漿の測定値乖離を防止する免疫測定法 - Google Patents
血清および血漿の測定値乖離を防止する免疫測定法 Download PDFInfo
- Publication number
- JP5189067B2 JP5189067B2 JP2009277755A JP2009277755A JP5189067B2 JP 5189067 B2 JP5189067 B2 JP 5189067B2 JP 2009277755 A JP2009277755 A JP 2009277755A JP 2009277755 A JP2009277755 A JP 2009277755A JP 5189067 B2 JP5189067 B2 JP 5189067B2
- Authority
- JP
- Japan
- Prior art keywords
- chelating agent
- metal compound
- immunoassay
- antigen
- plasma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000003018 immunoassay Methods 0.000 title claims description 33
- 238000005259 measurement Methods 0.000 title description 27
- 210000002966 serum Anatomy 0.000 title description 21
- 239000002738 chelating agent Substances 0.000 claims description 65
- 150000002736 metal compounds Chemical class 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 27
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 26
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 19
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 16
- 102000008946 Fibrinogen Human genes 0.000 claims description 14
- 108010049003 Fibrinogen Proteins 0.000 claims description 14
- 229940012952 fibrinogen Drugs 0.000 claims description 14
- 230000004520 agglutination Effects 0.000 claims description 7
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 159000000007 calcium salts Chemical class 0.000 claims description 5
- 159000000003 magnesium salts Chemical class 0.000 claims description 5
- 235000006408 oxalic acid Nutrition 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- IWTIBPIVCKUAHK-UHFFFAOYSA-N 3-[bis(2-carboxyethyl)amino]propanoic acid Chemical compound OC(=O)CCN(CCC(O)=O)CCC(O)=O IWTIBPIVCKUAHK-UHFFFAOYSA-N 0.000 claims description 4
- 239000013522 chelant Substances 0.000 claims description 4
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 description 43
- 210000002381 plasma Anatomy 0.000 description 40
- 239000000872 buffer Substances 0.000 description 31
- 239000000427 antigen Substances 0.000 description 27
- 102000036639 antigens Human genes 0.000 description 27
- 108091007433 antigens Proteins 0.000 description 27
- 239000000725 suspension Substances 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 22
- 239000008280 blood Substances 0.000 description 22
- 239000003153 chemical reaction reagent Substances 0.000 description 18
- 239000007853 buffer solution Substances 0.000 description 16
- 239000004816 latex Substances 0.000 description 15
- 229920000126 latex Polymers 0.000 description 15
- 239000000203 mixture Substances 0.000 description 13
- 239000012491 analyte Substances 0.000 description 7
- 230000002776 aggregation Effects 0.000 description 6
- 238000004220 aggregation Methods 0.000 description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- 239000001110 calcium chloride Substances 0.000 description 5
- 229910001628 calcium chloride Inorganic materials 0.000 description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 238000000691 measurement method Methods 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 230000001235 sensitizing effect Effects 0.000 description 4
- 239000006173 Good's buffer Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- -1 collodion Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Chemical compound [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229940038773 trisodium citrate Drugs 0.000 description 2
- ALWXETURCOIGIZ-UHFFFAOYSA-N 1-nitropropylbenzene Chemical compound CCC([N+]([O-])=O)C1=CC=CC=C1 ALWXETURCOIGIZ-UHFFFAOYSA-N 0.000 description 1
- AMBZRUJVCSJZSX-UHFFFAOYSA-N 4-imino-3-oxobutanoic acid Chemical compound OC(=O)CC(=O)C=N AMBZRUJVCSJZSX-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- CBOCVOKPQGJKKJ-UHFFFAOYSA-L Calcium formate Chemical compound [Ca+2].[O-]C=O.[O-]C=O CBOCVOKPQGJKKJ-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 229910001634 calcium fluoride Inorganic materials 0.000 description 1
- 229940095626 calcium fluoride Drugs 0.000 description 1
- 239000004281 calcium formate Substances 0.000 description 1
- 229940044172 calcium formate Drugs 0.000 description 1
- 235000019255 calcium formate Nutrition 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- BCFSVSISUGYRMF-UHFFFAOYSA-N calcium;dioxido(dioxo)chromium;dihydrate Chemical compound O.O.[Ca+2].[O-][Cr]([O-])(=O)=O BCFSVSISUGYRMF-UHFFFAOYSA-N 0.000 description 1
- BIOOACNPATUQFW-UHFFFAOYSA-N calcium;dioxido(dioxo)molybdenum Chemical compound [Ca+2].[O-][Mo]([O-])(=O)=O BIOOACNPATUQFW-UHFFFAOYSA-N 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- MHJAJDCZWVHCPF-UHFFFAOYSA-L dimagnesium phosphate Chemical compound [Mg+2].OP([O-])([O-])=O MHJAJDCZWVHCPF-UHFFFAOYSA-L 0.000 description 1
- 229910000395 dimagnesium phosphate Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940095529 heparin calcium Drugs 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- ARIXXGBZIGZIKW-UHFFFAOYSA-L magnesium dioxidophosphanium Chemical compound [Mg++].[O-][PH2]=O.[O-][PH2]=O ARIXXGBZIGZIKW-UHFFFAOYSA-L 0.000 description 1
- ORUIBWPALBXDOA-UHFFFAOYSA-L magnesium fluoride Chemical compound [F-].[F-].[Mg+2] ORUIBWPALBXDOA-UHFFFAOYSA-L 0.000 description 1
- 229910001635 magnesium fluoride Inorganic materials 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229910001381 magnesium hypophosphite Inorganic materials 0.000 description 1
- BLQJIBCZHWBKSL-UHFFFAOYSA-L magnesium iodide Chemical compound [Mg+2].[I-].[I-] BLQJIBCZHWBKSL-UHFFFAOYSA-L 0.000 description 1
- 229910001641 magnesium iodide Inorganic materials 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002102 polyvinyl toluene Polymers 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- PBYZMCDFOULPGH-UHFFFAOYSA-N tungstate Chemical compound [O-][W]([O-])(=O)=O PBYZMCDFOULPGH-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
また、試料としては病院検査等で外来患者や緊急検査として迅速性から血漿が用いられている。
(1)血漿中の被検成分を抗原抗体反応により光学的に測定する免疫測定法において、反応系にキレート剤および/または金属化合物を添加することを含む、血漿中のフィブリノーゲンの不溶化による測定値への影響を回避する方法、
(2)免疫測定法が凝集反応を利用した方法である、(1)の方法、
(3)キレート剤が配位数3個以下のものであり、且つフィブリノーゲンの不溶化による測定値への影響を回避し得るものである(1)または(2)の方法、
(4)クエン酸およびクエン酸化合物、シュウ酸およびシュウ酸化合物、イミノ二酢酸、ニトリロトリスメチレンホスホン酸三ナトリウム塩、ニトリロ三プロピオン酸、およびこれらのキレート剤の類似化合物からなる群から選択されるキレート剤の1種類以上を添加する、(3)の方法、
(5)添加されるキレート剤の最終濃度が0.01〜0.1mol/Lである(1)から(4)のいずれかの方法、
(6)金属化合物が、カルシウム塩またはマグネシウム塩である(1)または(2)に記載の方法、
(7)添加される金属化合物の最終濃度が0.001〜0.05mol/Lである(1)、(2)または(6)の方法、
(8)血漿中の被検成分を抗原抗体反応により光学的に測定する免疫測定方法において血漿中のフィブリノーゲンの不溶化による測定値への影響を回避するための、キレート剤および/または金属化合物を含む緩衝液組成物、
(9)クエン酸およびクエン酸化合物、シュウ酸およびシュウ酸化合物、イミノ二酢酸、ニトリロトリスメチレンホスホン酸三ナトリウム塩、ニトリロ三プロピオン酸、およびこれらのキレート剤の類似化合物からなる群から選択されるキレート剤の1種類以上を含む(8)の緩衝液組成物、
(10)キレート剤の濃度が0.01〜0.1mol/Lである(8)または(9)の緩衝液組成物、
(11)金属化合物が、カルシウム塩またはマグネシウム塩である(8)の緩衝液組成物、
(12)金属化合物の濃度が0.001〜0.05mol/Lである(10)または(11)の緩衝液組成物、および
(13)抗原または抗体感作粒子を含む(8)〜(12)のいずれかの緩衝液組成物。
本発明の方法に供される被検試料としては、血清、血漿、血液(全血)等の体液やその希釈物を挙げることができる。
〔参考例〕
RF測定試薬を用いて、緩衝液のキレート剤の種類における、同一ヒトから採血されたリウマチ因子を含む血清試料と血漿試料の誤差を調べた。この操作は具体的に次のように行なった。
次の組成から成る5種類の試薬を調製した。
5種類の試薬は緩衝液中に含まれるキレート剤が異なり、それ以外の成分は全て同じとした。
<共通成分>
緩衝液
Good緩衝液、pH8 0.1mol/L
Tween80 30%
キレート剤 0.05mol/L
ラテックス浮遊液
RF−ラテックスX1「生研」ラテックス浮遊液(デンカ生研)
<試薬>
緩衝液に以下のキレート剤を添加して測定を行った。
従来測定法
エチレンジアミン四酢酸(ナカライテスク)
試薬1
クエン酸三ナトリウム(ナカライテスク)
試薬2
シュウ酸(ナカライテスク)
試薬3
ニトリロ三プロピオン酸(同仁化学)
試薬4
イミノ二酢酸(同仁化学)
キレート剤の配位数を表1に示す。
測定値の差(IU/mL)=血漿試料の測定値−血清試料の測定値
結果を表2に示す。
〔実施例2〕 金属化合物の添加
実施例1で用いた試薬1の緩衝液に塩化カルシウムを添加しないものと添加したものを調製し、測定を行った。
<試薬>
緩衝液
good緩衝液、pH8 0.1mol/L
Tween80 30%
クエン酸三ナトリウム 0.05mol/L
塩化カルシウム 0.01mol/L
ラテックス浮遊液
RF−ラテックスX1「生研」ラテックス浮遊液(デンカ生研)
試薬1−1
塩化カルシウム無添加
試薬1−2
塩化カルシウム添加
測定値の差(IU/mL)=EDTA採血管血漿試料の測定値−血清試料の測定値
結果を表3に示す。
Claims (7)
- 界面活性剤を用いて、血漿中の被検成分を抗原抗体反応により光学的に測定する免疫測定法において、界面活性剤を含む反応系に配位数3個以下のキレート剤を含む、血漿中のフィブリノーゲンの不溶化による測定値への影響を回避する方法。
- EDTAおよび界面活性剤を含む反応系に配位数3個以下のキレート剤ならびに金属化合物を添加することを含む、請求項1記載の方法。
- 配位数3個以下のキレート剤がクエン酸およびクエン酸化合物、シュウ酸およびシュウ酸化合物、イミノ二酢酸、ニトリロトリスメチレンホスホン酸三ナトリウム塩、およびニトリロ三プロピオン酸からなる群から選択されるキレート剤の1種類以上を含む請求項1または2に記載の方法。
- 金属化合物が、カルシウム塩またはマグネシウム塩である請求項2または3に記載の方法。
- 免疫測定法が凝集反応を利用した方法である、請求項1〜4のいずれか1項に記載の方法。
- 添加されるキレート剤の最終濃度が0.01〜0.1mol/Lである請求項1〜5のいずれか1項に記載の方法。
- 添加される金属化合物の最終濃度が0.001〜0.05mol/Lである請求項2〜6のいずれか1項に記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009277755A JP5189067B2 (ja) | 2002-11-18 | 2009-12-07 | 血清および血漿の測定値乖離を防止する免疫測定法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002333714 | 2002-11-18 | ||
JP2002333714 | 2002-11-18 | ||
JP2009277755A JP5189067B2 (ja) | 2002-11-18 | 2009-12-07 | 血清および血漿の測定値乖離を防止する免疫測定法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004553191A Division JP4592422B2 (ja) | 2002-11-18 | 2003-11-18 | 血清および血漿の測定値乖離を防止する免疫測定法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010054516A JP2010054516A (ja) | 2010-03-11 |
JP5189067B2 true JP5189067B2 (ja) | 2013-04-24 |
Family
ID=32321708
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004553191A Expired - Lifetime JP4592422B2 (ja) | 2002-11-18 | 2003-11-18 | 血清および血漿の測定値乖離を防止する免疫測定法 |
JP2009277755A Expired - Lifetime JP5189067B2 (ja) | 2002-11-18 | 2009-12-07 | 血清および血漿の測定値乖離を防止する免疫測定法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004553191A Expired - Lifetime JP4592422B2 (ja) | 2002-11-18 | 2003-11-18 | 血清および血漿の測定値乖離を防止する免疫測定法 |
Country Status (2)
Country | Link |
---|---|
JP (2) | JP4592422B2 (ja) |
WO (1) | WO2004046723A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5143046B2 (ja) * | 2009-02-12 | 2013-02-13 | 富士フイルム株式会社 | 被験物質の測定方法及び該測定方法を実施するためのキット |
JP6646691B2 (ja) * | 2017-01-25 | 2020-02-14 | 三洋化成工業株式会社 | 抗原又は抗体固定化粒子及び免疫測定試薬の製造方法並びに免疫測定方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1226795A (en) * | 1983-06-06 | 1987-09-15 | Michael K. Hoskins | Stabilized coagulation control products |
JPS61280566A (ja) * | 1984-09-03 | 1986-12-11 | Hiroaki Sawai | 2’−5’−オリゴアデニル酸の免疫学的直接定量法 |
JPH0682450A (ja) * | 1992-09-04 | 1994-03-22 | Eiken Chem Co Ltd | 免疫学的測定試薬 |
JPH0720128A (ja) * | 1993-07-06 | 1995-01-24 | Tosoh Corp | 生体試料中微量成分の測定方法 |
US5817525A (en) * | 1995-05-19 | 1998-10-06 | Chiron Diagnostics Corporation | Stable protein solutions for diagnostics and method of making and using the same |
JP2000210380A (ja) * | 1999-01-26 | 2000-08-02 | Nagase & Co Ltd | 血液凝固阻止剤及びそれを収納した採血容器 |
KR20030021182A (ko) * | 2000-06-30 | 2003-03-12 | 교와메덱스 코리미티드 | 불용성담체입자 비탁면역측정용시약 |
-
2003
- 2003-11-18 JP JP2004553191A patent/JP4592422B2/ja not_active Expired - Lifetime
- 2003-11-18 WO PCT/JP2003/014654 patent/WO2004046723A1/ja active Application Filing
-
2009
- 2009-12-07 JP JP2009277755A patent/JP5189067B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO2004046723A1 (ja) | 2004-06-03 |
JPWO2004046723A1 (ja) | 2006-03-16 |
JP2010054516A (ja) | 2010-03-11 |
JP4592422B2 (ja) | 2010-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH07508102A (ja) | アッセイ | |
EP0481020A1 (en) | IMMUNOASSAY METHOD WITH MONEY ENRICHMENT AND GOLD LABELING. | |
WO2002073203A1 (fr) | Procede de mesure de sang entier | |
US9482674B2 (en) | Serological methods and diagnostic tests for syphilis antibodies | |
JP5189067B2 (ja) | 血清および血漿の測定値乖離を防止する免疫測定法 | |
JP4653574B2 (ja) | ヘモグロビンA1cの測定方法 | |
CN107044977A (zh) | 一种酪氨酸磷酸酶抗体化学发光免疫检测试剂盒及其制备方法 | |
JP4418895B2 (ja) | 非特異的反応抑制剤、非特異的反応の抑制方法、免疫学的測定方法及び免疫学的測定試薬 | |
JP3771413B2 (ja) | 抗リン脂質抗体測定試薬及びその製造方法ならびに抗リン脂質抗体測定方法 | |
CN116413445A (zh) | 一种检测总甲状腺素含量的检测卡、试剂盒及其检测方法 | |
WO1997001099A1 (fr) | Dosage immunologique a l'or colloidal | |
JP4567326B2 (ja) | 全血を用いる測定法 | |
WO2024038863A1 (ja) | 免疫分析方法及び試薬 | |
JP2004251851A (ja) | 糞便成分の検査方法 | |
JP2684425B2 (ja) | ラテックス試薬 | |
JP3916189B2 (ja) | イムノアッセイ用試薬及びイムノアッセイ | |
JP3520757B2 (ja) | 非特異反応吸収剤及び該吸収剤を用いる免疫測定法 | |
JP2004117068A (ja) | 免疫測定試薬および免疫測定方法 | |
JP2000275245A (ja) | 免疫測定試薬及び免疫測定方法 | |
JPH04324358A (ja) | 糞便中のヒトヘモグロビン測定法 | |
JP3692055B2 (ja) | 抗原抗体反応の判定方法 | |
JP2022161884A (ja) | 自動分析装置の測定値の正確性を向上させる方法 | |
WO2021186003A1 (en) | Improved lateral flow formats for optimized flow and increased sensitivity | |
CN115201181A (zh) | 一种排除磁微粒化学发光检测中血细胞干扰的方法 | |
CN106771131A (zh) | 一种抗线粒体抗体m2型化学发光免疫检测试剂盒及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091207 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111129 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120821 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121019 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130115 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130123 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160201 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5189067 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |